COVID-19, asthma, and biological therapies: What we need to know.
AAAAI, American Academy of Allergy, Asthma and Immunology
ACAAI, American College of Allergy, Asthma and Immunology
ACE2, Angiotensin-converting enzyme 2
ADCC, Antibody-Dependent Cell-mediated Cytotoxicity
AEs, Adverse events
Asthma
BTS, British Thoracic Society
Biologics
COVID-19
COVID-19, Coronavirus Disease 2019
DNA, Deoxyribonucleic acid
EBM, Evidence Based Medicine
ELF, European Lung Foundation
ERS, European Respiratory Society
FDA, Food and Drug Administration
GINA, Global Initiative for Asthma
GSK, Glaxo Smith Kline
ICS, inhaled corticosteroids
ICU, Intensive Care Unit
IL13, Interleukin 13
IL4, Interleukin 4
IL5, Interleukin 5
IL5Ra, Interleukin 5 alfa receptor
IL5r, Interleukin 5 receptor
IL6, Interleukin 6
IgE, Immunoglobulin E
NHLBI, National Heart, Lung, and Blood Institute
OCS, Oral corticosteroids
PDGFRA, Platelet-Derived Growth Factor Receptor A
PROSE study, Preventative Omalizumab or Step-up therapy for fall Exacerbations study
Pandemic
RCTs, Randomized Controlled Trials
SAEs, Serious Adverse Events
SARP, Severe Asthma Research Programme
SARS-CoV-2
SARS-CoV-2, Severe Acute Respiratory Syndrome Coronavirus 2
SC, Subcutaneous
SIAAIC, Italian Society of Allergy, Asthma and Clinical Immunology
Severe
T2, Type 2 inflammation
TMPRSS2, Transmembrane Protease Serine 2 Enzyme
Treatment
USA, United States of America
mAb, Monoclonal antibody
Journal
The World Allergy Organization journal
ISSN: 1939-4551
Titre abrégé: World Allergy Organ J
Pays: United States
ID NLM: 101481283
Informations de publication
Date de publication:
May 2020
May 2020
Historique:
received:
23
04
2020
revised:
08
05
2020
accepted:
11
05
2020
pubmed:
20
5
2020
medline:
20
5
2020
entrez:
20
5
2020
Statut:
epublish
Résumé
Managing patients with severe asthma during the coronavirus pandemic and COVID-19 is a challenge. Authorities and physicians are still learning how COVID-19 affects people with underlying diseases, and severe asthma is not an exception. Unless relevant data emerge that change our understanding of the relative safety of medications indicated in patients with asthma during this pandemic, clinicians must follow the recommendations of current evidence-based guidelines for preventing loss of control and exacerbations. Also, with the absence of data that would indicate any potential harm, current advice is to continue the administration of biological therapies during the COVID-19 pandemic in patients with asthma for whom such therapies are clearly indicated and have been effective. For patients with severe asthma infected by SARS-CoV-2, the decision to maintain or postpone biological therapy until the patient recovers should be a case-by-case based decision supported by a multidisciplinary team. A registry of cases of COVID-19 in patients with severe asthma, including those treated with biologics, will help to address a clinical challenge in which we have more questions than answers.
Identifiants
pubmed: 32426090
doi: 10.1016/j.waojou.2020.100126
pii: S1939-4551(20)30029-6
pii: 100126
pmc: PMC7229954
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
100126Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Informations de copyright
© 2020 The Authors.
Références
J Allergy Clin Immunol. 2019 May;143(5):1742-1751.e7
pubmed: 30359681
Am J Clin Dermatol. 2019 Jun;20(3):443-456
pubmed: 31066001
N Engl J Med. 2018 Jun 28;378(26):2486-2496
pubmed: 29782217
MMWR Morb Mortal Wkly Rep. 2020 Apr 10;69(14):422-426
pubmed: 32271728
JAMA. 2020 Apr 6;:
pubmed: 32250385
Am J Respir Crit Care Med. 2017 Oct 15;196(8):985-992
pubmed: 28608756
Am J Respir Crit Care Med. 2018 Mar 15;197(6):757-767
pubmed: 29161116
Lancet. 2016 Jul 2;388(10039):31-44
pubmed: 27130691
J Clin Virol. 2004 Dec;31(4):304-9
pubmed: 15494274
Allergy. 2020 May;75(5):1043-1057
pubmed: 32064642
J Allergy Clin Immunol Pract. 2017 Nov - Dec;5(6):1572-1581.e3
pubmed: 29122156
Am J Respir Crit Care Med. 2020 Jul 1;202(1):83-90
pubmed: 32348692
Pulm Ther. 2020 Jun;6(1):47-66
pubmed: 32048241
MMWR Morb Mortal Wkly Rep. 2020 Apr 17;69(15):458-464
pubmed: 32298251
J Allergy Clin Immunol Pract. 2020 May;8(5):1477-1488.e5
pubmed: 32224232
J Allergy Clin Immunol. 2020 Jul;146(1):110-118
pubmed: 32294485
Lancet Respir Med. 2019 Jan;7(1):46-59
pubmed: 30416083
J Allergy Clin Immunol. 2020 Feb 1;:
pubmed: 32018030
Lancet. 2012 Aug 18;380(9842):651-9
pubmed: 22901886
J Biol Regul Homeost Agents. 2020 Mar 14;34(2):327-331
pubmed: 32171193
Clin Ther. 2016 Sep;38(9):2058-2070.e1
pubmed: 27553751
Lancet Respir Med. 2020 May;8(5):436-438
pubmed: 32251625
Lancet. 2016 Oct 29;388(10056):2115-2127
pubmed: 27609408
Lancet. 2016 Oct 29;388(10056):2128-2141
pubmed: 27609406
J Med Virol. 2020 Apr 15;:
pubmed: 32293716
Allergy. 2020 Jul;75(7):1730-1741
pubmed: 32077115
Lancet Respir Med. 2020 Apr;8(4):e21
pubmed: 32171062
N Engl J Med. 2019 Apr 4;380(14):1336-1346
pubmed: 30943337
N Engl J Med. 2020 Jun 11;382(24):2327-2336
pubmed: 32275812
JAMA. 2020 Apr 13;:
pubmed: 32282022
N Engl J Med. 2020 May 21;382(21):2012-2022
pubmed: 32227758